Trial
NCT04223648
Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
Early Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
AstraZeneca
Condition
Malignant Melanoma
Intervention
tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
Why stopped
Funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-22